Movement Alert|SELLAS Life Sciences Falls 8.6% in Regular Trading, Trading at $11.73

Market Focus07-16 22:42

On July 16, SELLAS Life Sciences fell 8.6% in regular trading, trading at $11.73 USD/share, with Turnover of $36.72 million.

Within the Biotechnology sector where SELLAS Life Sciences belongs, among individual stocks, AbbVie up 2.75%, Amgen up 2.06%, Gilead Sciences up 1.18%, Vertex Pharmaceuticals up 0.83%, Moderna down 4.29%.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate is Galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for acute myeloid leukemia, and SLS009, a highly selective CDK9 inhibitor in Phase 2 trials for first-line AML treatment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment